• <table id="gigg0"></table>
  • west china medical publishers
    Author
    • Title
    • Author
    • Keyword
    • Abstract
    Advance search
    Advance search

    Search

    find Author "梁峰" 3 results
    • 頸椎椎管內/ 外骨軟骨瘤一例

      略。。。

      Release date:2016-08-31 05:49 Export PDF Favorites Scan
    • EXPERIMENTAL STUDY ON CHONDROGENIC DIFFERENTIATION OF RABBIT ADIPOSE-DERIVED STEM CELLS TREATED WITH GROWTH DIFFERENTIATION FACTOR 5

      Objective To investigate the feasibil ity and effect of inducing adi pose-derived stem cells (ADSCs) treated with growth differentiation factor 5 (GDF-5) to undergo chondrogenic differentiation in vitro. Methods Six healthy Japanese rabbits aged 3 months (2-3 kg) of clean grade were chosen, irrespective of sex. ADSCs were isolated and cultured with collagenase digestion, then were detected and identified by vimentin immunohistochemistry and CD44, CD49d, CD106immunofluorescence staining. ADSCs at passage 3 were used and the cell density was adjusted to 1 × 106/mL, then the ADSCs were treated with 0, 10, 100 ng/mL GDF-5 and common cultural medium, respectively. The morphology changes of the induced ADSCs were observed by inverted contrast phase microscope and their growth state were detected by MTT. The mRNA quantities of Col II and proteoglycan expressed by the induced ADSCs were detected with RT-PCR. The Col II proteoglycan synthesized by the induced ADSCs were detected with alcian blue staining, toluidine blue staining, immunohistochemistry staining, and Western blot method. Results ADSCs mostly presented small sphere, fusiform and polygon shape with positive expression of CD44 and CD49d and negative expression of CD106 and vimentin. The ADSCs treated with 100 ng/mL GDF-5 presented sphere or sphere-l ike change and vigorous prol iferation. The mRNA quantities of Col II and proteoglycan synthesized by the induced ADSCs treated with 0, 10, 100 ng/mL GDF-5 and common cultural medium increased in a dose-dependent manner at 7 days. There were significant differences among all the groups (P lt; 0.05), except that no significant difference was evident between the 0 ng/mL group and the 10 ng/mL group (P gt; 0.05). When ADSCs were treated with 100 ng/mL GDF-5 for 14 days, the Col II and the mRNA and protein quantities of ptoteoglycan reached the peak, and the results of alcian blue, toluidine blue and Col IIimmunohistochemistry staining were positive. Conclusion ADSCs treated with certain concentration of GDF-5 have higher expression of Col II and proteoglycan and possess partial biological function of chondrocyte.

      Release date:2016-09-01 09:05 Export PDF Favorites Scan
    • 一期前路病灶清除植骨及內固定術治療頸椎及頸胸段脊柱結核

      目的 總結一期前路病灶清除、椎體間植骨及前路內固定治療頸椎及頸胸段脊柱結核的臨床療效,探討重建脊柱穩定性的必要性和安全性。 方法 2002 年4 月- 2006 年3 月,采用一期前路病灶清除、椎體間植骨及前路內固定治療13 例頸椎及頸胸段脊柱結核患者。男8 例,女5 例;年齡21 ~ 58 歲。病程1 ~ 7 個月,平均4 個月。頸椎結核10 例,頸胸段結核3 例。術前X 線片、CT、MRI 檢查示病變部位為:C3、4 1 例,C5 2 例,C5、6 3 例,C6、7 4 例,C7、T12 例,C7 ~ T2 1 例。后凸Cobb 角為20 ~ 50°,平均35.7°。神經功能ASIA 分級:B 級1 例,C 級4 例,D 級6 例,E 級2 例。術前血沉34 ~ 78 mm/h,平均42 mm/h。 結果 術后患者均獲隨訪,隨訪時間9 ~ 34 個月,平均14 個月。均未出現傷口深部感染或竇道形成,平均1.5 個月血沉降至20 mm/h 以下。患者植骨均完全融合,融合時間3 ~ 5 個月,平均3.4 個月。術后后凸Cobb 角17 ~ 39°,平均29.3°;隨訪14 個月時為9 ~ 21°,平均14.5°。神經功能除1 例B 級恢復至D 級外,余均達E級。 結論 一期前路病灶清除同期植骨內固定治療頸椎及頸胸段脊柱結核能徹底清除病灶、防止復發、矯正畸形、重建脊柱穩定性,促進脊柱植骨融合,提高脊柱結核的治愈率。

      Release date:2016-09-01 09:17 Export PDF Favorites Scan
    1 pages Previous 1 Next

    Format

    Content

  • <table id="gigg0"></table>
  • 松坂南